Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry.

[1]  Scott E. Smith,et al.  Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma , 2017, The Lancet. Haematology.

[2]  A. Palumbo,et al.  Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis , 2017, Leukemia.

[3]  Sin-Ho Jung,et al.  Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[5]  B. Barlogie,et al.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial , 2017, The Lancet.

[6]  R. Fonseca,et al.  Trends in overall survival and costs of multiple myeloma, 2000–2014 , 2016, Leukemia.

[7]  J. Hardin,et al.  Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Any or Lenalidomide Maintenance after Autologous Stem Cell Transplant in the Connect® MM Disease Registry , 2016 .

[8]  M. Mohty,et al.  Real-World Treatment Patterns and Health Care Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Cohort Review in France , 2016 .

[9]  P. Richardson,et al.  Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). , 2016 .

[10]  J. Hardin,et al.  Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide , 2016, Leukemia & lymphoma.

[11]  R. Vij,et al.  Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  Shankar Srinivasan,et al.  Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. , 2015, Clinical lymphoma, myeloma & leukemia.

[13]  S. Arikian,et al.  Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma , 2015, Current medical research and opinion.

[14]  M. Boccadoro,et al.  Autologous transplantation and maintenance therapy in multiple myeloma. , 2014, The New England journal of medicine.

[15]  Christian Jacques,et al.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. , 2014, The New England journal of medicine.

[16]  P. Sonneveld,et al.  Real‐world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents , 2013, Journal of clinical pharmacy and therapeutics.

[17]  M. Beksac,et al.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma. , 2012, The New England journal of medicine.

[18]  B. Pégourié,et al.  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[19]  K. Owzar,et al.  Lenalidomide after stem-cell transplantation for multiple myeloma. , 2012, The New England journal of medicine.

[20]  R A Kyle,et al.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2009, Leukemia.

[21]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[23]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[24]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .